Fda provides clearance to ind application for type 1 diabetes therapy sab-142 by sab biotherapeutics

Miami, may 21, 2024 (globe newswire) -- sab biotherapeutics (nasdaq: sabs) (the “company” or “sab”), today announced that the u.s. food and drug administration (fda) has provided clearance for the company's investigational new drug (ind) application to proceed for its phase 1 clinical trial for type 1 diabetes (t1d) therapy sab-142. sab is a clinical-stage biopharmaceutical company with a novel immunotherapy platform developing a human anti-thymocyte immunoglobulin (higg) for delaying the onset or progression of t1d.
SABS Ratings Summary
SABS Quant Ranking